Skip to content

Effect of intrauterine administration of granulocyte-colony stimulating factor (GCSF) in IVF cycles on the fertility rate of infertile women

Effect of intrauterine administration of granulocyte-colony stimulating factor (GCSF) in IVF cycles on the fertility rate of infertile women suffering from moderate to severe endometriosis

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20110731007165N7
Enrollment
66
Registered
2019-09-10
Start date
2019-01-15
Completion date
Unknown
Last updated
2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility. Female infertility of other origin

Interventions

Intervention 1: Intervention: Immediately after ovarian puncture, 300µ GCSF is injected into the uterine cavity. Intervention 2: Control group: no intervention.

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: First time IVF due to infertility Moderate to severe endometriosis (according to laparoscopic criteria, moderate endometriosis was defined as Adhesion affecting Fallopian tubes or ovaries, and severe endometriosis was defined as the involvement of Fallopian tubes, ovaries, and cul-de-sac) Age 18-40 years Fertility due to endometriosis Moderate -to –severe endometriosis was characterized by endometrial glands and stroma at least 5 mm beneath the peritoneum or an ovarian endometriotic cyst (endometrioma)

Exclusion criteria

Exclusion criteria: Male factor infertility. Evidence of a significant decrease in the ovarian reserve (FSH>11, AMH<0.5, decreased AFC), Endocrine disorders (diabetes, thyroid diseases, hyperprolactinemia, hypothalamic amenorrhea, etc.) , confirmed medical and immunologic diseases (SLE, rheumatoid arthritis, antiphospholipid syndrome, cardiovascular, liver, and renal diseases), and congenital uterine anomalies and uterine cavity disorder (bicornuate uterus, unicornuate uterus, Asherman syndrome, myoma, polyps, etc.). Donation candidates (ovum donation and surrogate utrus) were also excluded from the study

Design outcomes

Primary

MeasureTime frame
Clinical pregnancy. Timepoint: 3 weeks after embryo transfer. Method of measurement: Vaginal ultrasound.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Ladan Kashani

Tehran University of Medical Sciences

Kashani_ladan@tums.ac.ir+98 21 7788 3195

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026